Vitro Biopharma, Inc.SEC Filings
|
|
All SEC filings by Vitro Biopharma, Inc. (VTRO) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q | Quarterly report | View Diff | Jun 15, 2026 | |
| 10-Q | Quarterly report | View Diff | Mar 16, 2026 | |
| 10-K | Annual report | View Diff | Feb 13, 2026 | |
| NT 10-K | Notice of late annual filing | Jan 29, 2026 | ||
| 10-Q | Quarterly report | View Diff | Sep 12, 2025 | |
| 10-Q | Quarterly report | View Diff | Jun 20, 2025 | |
| NT 10-Q | Notice of late quarterly filing | Jun 16, 2025 | ||
| 10-Q | Quarterly report | View Diff | Mar 20, 2025 | |
| NT 10-Q | Notice of late quarterly filing | Mar 17, 2025 | ||
| 10-K | Annual report | View Diff | Jan 28, 2025 |
Events
| 8-K | Entry Into a Material Definitive Agreement | Jul 22, 2024 | ||
| 8-K | Entry Into a Material Definitive Agreement | Jun 26, 2024 | ||
| 8-K | Entry Into a Material Definitive Agreement | May 17, 2024 | ||
| 8-K | Entry Into a Material Definitive Agreement | Apr 17, 2024 | ||
| 8-K | Vitro Biopharma Announces New Chief Financial Officer | Jan 22, 2024 | ||
| 8-K | Entry Into a Material Definitive Agreement | Jan 12, 2024 | ||
| 8-K | Entry Into a Material Definitive Agreement | Nov 22, 2023 | ||
| 8-K | Entry Into a Material Definitive Agreement | Jul 19, 2023 | ||
| 8-K | Material Modifications to Rights of Security Holders | Jul 7, 2023 | ||
| 8-K | Entry Into a Material Definitive Agreement | Jun 16, 2023 |
Registrations and Prospectuses
| D | $15.00 Mm in Equity, Sold $100.00 K, 1 Investor | Jun 11, 2025 | ||
| S-1/A | IPO registration | View Diff | Sep 5, 2024 | |
| S-1/A | IPO registration | View Diff | Aug 23, 2024 | |
| S-1/A | IPO registration | View Diff | Aug 8, 2024 | |
| S-1/A | IPO registration | View Diff | Jul 1, 2024 | |
| S-1/A | IPO registration | View Diff | Feb 2, 2024 | |
| S-1/A | IPO registration | View Diff | Dec 12, 2023 | |
| D | $3.00 Mm in Debt / Options, Sold $2.00 Mm, 1 Investor | Dec 1, 2023 | ||
| S-1/A | IPO registration | View Diff | Aug 28, 2023 | |
| 8-A12B | Registration of securities on exchange | Aug 1, 2023 |
Proxies
Other
| EFFECT | Notice of effectiveness | Sep 12, 2024 | ||
| CORRESP | Correspondence with SEC | Sep 10, 2024 | ||
| CORRESP | Correspondence with SEC | Sep 10, 2024 | ||
| CORRESP | Correspondence with SEC | Aug 29, 2024 | ||
| UPLOAD | Letter from SEC | Aug 29, 2024 | ||
| CORRESP | Correspondence with SEC | Aug 23, 2024 | ||
| UPLOAD | Letter from SEC | Aug 20, 2024 | ||
| CORRESP | Correspondence with SEC | Aug 8, 2024 | ||
| UPLOAD | Letter from SEC | Jul 26, 2024 | ||
| CORRESP | Correspondence with SEC | Jul 1, 2024 |
Ownership
| 3/A | Christopher Furman | Jun 30, 2023 | ||
| SC 13G | Vitro Biopharma, Inc. | Feb 15, 2023 | ||
| SC 13G | Vitro Biopharma, Inc. | Feb 14, 2023 | ||
| SC 13D | Vitro Biopharma, Inc. | Dec 2, 2022 | ||
| SC 13D | Beneficial ownership report | Dec 2, 2022 | ||
| 3 | Jack Zamora | Nov 17, 2022 | ||
| 3 | Nathan Haas | Nov 14, 2022 | ||
| 3 | John Packs | Nov 14, 2022 | ||
| 3 | Christopher Furman | Nov 14, 2022 | ||
| 3 | James R Musick | Nov 14, 2022 |